Quantum BioPharma Ltd. (NASDAQ: QNTM) has signed a Study Start-Up Agreement with Thermo Fisher Scientific's clinical research business to support the Phase 2 clinical trial of Lucid-MS, its investigational drug candidate for progressive multiple sclerosis (MS). The agreement follows U.S. Food and Drug Administration clearance of the company's Investigational New Drug application in August 2026, moving the program toward clinical implementation with a contract research organization experienced in central nervous system and MS studies.
The news matters because Lucid-MS takes a different approach from many existing MS treatments, which primarily target the immune system. Lucid-MS is designed to protect myelin, the protective coating around nerve fibers, by inhibiting PAD2, an enzyme implicated in myelin damage. If successful, this mechanism could offer a new treatment option for progressive MS, a condition with limited therapeutic alternatives. The randomized, double-blind, placebo-controlled trial will evaluate the candidate's safety, tolerability and efficacy using clinical and radiological measures.
While preclinical research and Phase 1 testing have provided encouraging findings, Lucid-MS remains investigational, and the company has not yet announced enrollment dates or trial sites. Investors and patients should note that clinical-stage biopharmaceutical investments carry inherent risks, and the timeline for potential commercialization remains uncertain. For full details, see the complete article.
Quantum BioPharma describes itself as a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., Quantum is focused on the research and development of Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation in preclinical models. More information is available at www.QuantumBioPharma.com.
The announcement was distributed through InvestorWire, a specialized communications platform focused on advanced wire-grade press release syndication for private and public companies and the investment community. InvestorWire is one of 75+ brands within the Dynamic Brand Portfolio at IBN, which delivers access to a vast network of wire solutions, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution and tailored corporate communications solutions. For the latest updates on QNTM, visit the company's newsroom at https://ibn.fm/QNTM.
